NASDAQ:IBTB iShares iBonds Dec 2022 Term Treasury ETF (IBTB) Price, Holdings, & News → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free IBTB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$25.38▼$25.4050-Day Range$25.42▼$25.4352-Week Range$25.40▼$25.58Volume115,706 shsAverage Volume19,325 shsMarket Capitalization$76.17 millionAssets Under Management$180.26 millionDividend Yield0.71%Net Expense Ratio0.07% Stock AnalysisStock Analysis Get iShares iBonds Dec 2022 Term Treasury ETF alerts: Email Address About iShares iBonds Dec 2022 Term Treasury ETFRead More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> IBTB ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive IBTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares iBonds Dec 2022 Term Treasury ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssueriShares Fund NameiShares iBonds Dec 2022 Term Treasury ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBTB Inception Date2/25/2020 Fund ManagerJames Mauro, Scott Radell WebN/A Phone14089961010Fund Focus Asset ClassFixed Income BenchmarkICE 2022 Maturity US Treasury Index CategoryU.S. Government FocusTreasury Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$180.26 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorState Street Bank and Trust Company AdvisorBlackRock Fund Advisors CustodianState Street Bank and Trust Company DistributorBlackRock Investments, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Miscellaneous Outstanding Shares3,000,000BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> iShares iBonds Dec 2022 Term Treasury ETF ExpensesTypeIBTBTreasury ETFsFixed Income ETFsNASDAQ ETFsAll ETFsManagement Fee0.07%0.28%0.32%0.48%0.51%Other Expenses0.00%0.35%0.27%0.34%0.58%Total Expense0.07%0.37%0.40%0.58%0.70%Fee Waiver0.00%-0.32%-0.24%-0.22%-0.57%Net Expense0.07%0.33%0.35%0.54%0.58% iShares iBonds Dec 2022 Term Treasury ETF (IBTB)Full Holdings Details Similar ETFsiShares iBonds Dec 2031 Term Treasury ETFNASDAQ:IBTLiShares iBonds Dec 2032 Term Treasury ETFNASDAQ:IBTMiShares iBonds Dec 2033 Term Treasury ETFNASDAQ:IBTOiShares iBonds Dec 2030 Term Treasury ETFNASDAQ:IBTKiShares iBonds Dec 2029 Term Treasury ETFNASDAQ:IBTJ IBTB ETF - Frequently Asked Questions What does IBTB invest in? iShares iBonds Dec 2022 Term Treasury ETF is a fixed income fund issued by iShares. IBTB focuses on treasury investments and follows the ICE 2022 Maturity US Treasury Index. The fund's investments total to approximately $180.26 million assets under management. What is the management fee for iShares iBonds Dec 2022 Term Treasury ETF? iShares iBonds Dec 2022 Term Treasury ETF's management fee is 0.07% and has no other recorded expenses or fee waivers. The net expense ratio for IBTB is 0.07%. This page (NASDAQ:IBTB) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares iBonds Dec 2022 Term Treasury ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.